Study to Assess the Safety, Tolerability, Pharmacokinetics, and Effect on Disease Progression of BIIB078 Administered to Previously Treated Adults C9ORF72-Associated Amyotrophic Lateral Sclerosis (ALS)

PHASE1TerminatedINTERVENTIONAL
Enrollment

75

Participants

Timeline

Start Date

April 28, 2020

Primary Completion Date

May 3, 2022

Study Completion Date

May 3, 2022

Conditions
Amyotrophic Lateral Sclerosis
Interventions
DRUG

BIIB078

Administered as specified in the treatment arm.

Trial Locations (21)

9007

Research Site, Sankt Gallen

10032

Research Site, New York

21287

Research Site, Baltimore

30322

Research Site, Atlanta

32224

Research Site, Jacksonville

33136

Research Site, Miami

37920

Research Site, Knoxville

63110

Research Site, St Louis

68506

Research Site, Lincoln

90048

Research Site, Los Angeles

92037

Research Site, La Jolla

94304

Research Site, Palo Alto

02114

Research Site, Boston

T2N 1N4

Research Site, Calgary

T6G 2B7

Research Site, Edmonton

M4N 3M5

Research Site, Toronto

H3A 2B4

Research Site, Montreal

3508 GA

Research Site, Utrecht

NW1 2PG

Research Site, London

SE5 9RS

Research Site, London

S10 2HQ

Research Site, Sheffield

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Biogen

INDUSTRY

NCT04288856 - Study to Assess the Safety, Tolerability, Pharmacokinetics, and Effect on Disease Progression of BIIB078 Administered to Previously Treated Adults C9ORF72-Associated Amyotrophic Lateral Sclerosis (ALS) | Biotech Hunter | Biotech Hunter